explore -WSS

explore

author：comprehensive 2025-09-06 02:06:08 - browse：666

Adobe

The medical device industry is split on whether a proposed new Medicare reimbursement pathway will do anything to soothe their insurance coverage woes.

Device makers have long complained that the unclear, rocky road to payment kills innovative companies. So they were thrilled when the Trump administration proposed a rule that would have guaranteed four years of Medicare coverage of approved devices deemed “breakthroughs” by the Food and Drug Administration. They hoped private payers would follow suit. But in 2021, under a new administration and a push for more device scrutiny, the Centers for Medicare and Medicaid pulled back on the idea, promising a replacement that would streamline coverage for innovative devices while ensuring safe, high-quality care.

The pathway put forth last week, called Transitional Coverage for Emerging Technologies (TCET), is only a notice, not yet a rule that would grant CMS new powers. The program applies solely to devices that have earned a place in the FDA’s breakthrough device program, which was established to identify devices that the agency believed could provide “more effective” treatment or diagnosis of serious conditions than the current standard of care. But because those devices can be brought to market with less certainty in their benefits and risks than other products, experts said, the idea of automatic reimbursement was dicey.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： Videos point to link between seizures and unexplained toddler deaths

hotspot

WSS

J&J to buy cancer drug developer Ambrx Biopharma

Chronically ill young patients struggle to find fertility info

Goldman Sachs launches $650M fund for life science investments

For one rare type of lung cancer, Pfizer pill reduces progression by 81%

ASCO: AstraZeneca says CAR

NIH documents show early flaws of $1.6 billion long Covid program

hotspot

explore

explore

New air purifier tech could be key to improving indoor air quality

For one rare type of lung cancer, Pfizer pill reduces progression by 81%

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

ChatGPT in medicine: STAT answers readers' burning questions

FDA's Pazdur wants cancer trials to range beyond China alone

New air purifier tech could be key to improving indoor air quality

AdventHealth escalates lawsuit against insurance vendor Multiplan

Trump demands the U.S. pay no more for drugs than other countries … again

New weight loss drugs work. But how can they best be used?

Wikipedia

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

Insitro, AI biotech unicorn, brings cash, new research to JPM 2024

UCB departs biotech trade group BIO

UCB departs biotech trade group BIO

NIH documents show early flaws of $1.6 billion long Covid program

U.K. sequencing study surfaces new findings about tumor DNA

hotspot

hotspot

explore

Wikipedia